A German drug maker has reached a mutual termination with a Japanese pharmaceutical company in regards to a new potential treatment method for multiple sclerosis (MS).
Merck KGaA released a statement saying that ceralifimod, which was in the second phase of trials, did not meet its "threshold for continued investment".
The German firm had been working with Ono Pharmaceutical to develop this potential treatment for the debilitating neurological condition and this signifies another failed attempt by the former to enter the oral MS treatment market.
Merck insisted it remained committed to enhancing the lives of those with the inflammatory condition by working with other firms to develop "high-quality candidate molecules".
Around 100,000 people are thought to be affected by MS in the UK and approximately three times as many women than men have it. Symptoms are wide-ranging, but the more common ones include fatigue, vision problems and difficulties with walking.
Read about Barchester expertise in offering multiple sclerosis support.